Second Sight Medical Products (NASDAQ:EYES) Given a $5.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $5.00 price objective on Second Sight Medical Products (NASDAQ:EYES) in a research note published on Monday, February 5th. The firm currently has a buy rating on the medical device company’s stock.

Separately, Zacks Investment Research upgraded Second Sight Medical Products from a sell rating to a hold rating in a report on Monday, January 8th.

Shares of Second Sight Medical Products (NASDAQ:EYES) opened at $1.69 on Monday. Second Sight Medical Products has a 1-year low of $0.90 and a 1-year high of $2.58. The stock has a market capitalization of $96.00, a price-to-earnings ratio of -2.64 and a beta of 3.46.

Several large investors have recently made changes to their positions in EYES. Vanguard Group Inc. raised its holdings in shares of Second Sight Medical Products by 0.7% during the second quarter. Vanguard Group Inc. now owns 843,462 shares of the medical device company’s stock worth $1,062,000 after acquiring an additional 5,973 shares in the last quarter. Sigma Planning Corp purchased a new stake in shares of Second Sight Medical Products during the fourth quarter worth $144,000. Finally, Virtu Financial LLC purchased a new stake in shares of Second Sight Medical Products during the fourth quarter worth $759,000. Institutional investors and hedge funds own 12.69% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/13/second-sight-medical-products-eyes-given-a-5-00-price-target-at-hc-wainwright.html.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply